by andre | Jul 27, 2026 | KoreFeed
SARCOMATRIX THERAPEUTICS CORP. FOR IMMEDIATE RELEASE Sarcomatrix Applies SarcoVista™ Translational Modeling to First-in-Human Dose Selection for S-969 The preclinical-stage company is using its proprietary modeling platform to inform the starting dose and escalation...
by andre | Jul 23, 2026 | KoreFeed
RENO, Nev., July 24, 2026 (KOREWIRE) … Sarcomatrix Therapeutics Corp., a Delaware corporation based in Reno, Nevada, today announced that its investment round is open to accredited investors. The round is being conducted under Regulation D, Rule 506(c), and is...
